In addition to solid cancers, we also identified a number of hematological malignancies that co-express high levels of CD80 and PTK2, highlighting potential opportunities for the development of FAK inhibitors for the treatment of some blood cancers. This evidence concerns the gene PTK2 and hematopoietic and lymphoid system neoplasm.